As of Oct 21
| +0.04 / +1.36%|
The 4 analysts offering 12-month price forecasts for Endocyte Inc have a median target of 7.50, with a high estimate of 10.00 and a low estimate of 5.00. The median estimate represents a +150.84% increase from the last price of 2.99.
The current consensus among 4 polled investment analysts is to Buy stock in Endocyte Inc. This rating has held steady since October, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.